Sildenafil ODT is one of 207 small molecule programs targeting Oligohydramnios. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
120 competitors in Chronic Obstructive Pulmonary Disease
EXDENSUR
Lunsekimig
Sildenafil ODT
Tozorakimab
CM310
Astegolimab
Titrated Oxygen
Calciferol
Duragesic
Verekitug
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details